(Q44657843)

5 December 2017

title

Acute hepatitis induced by alpha-interferon, associated with viral clearance, in chronic hepatitis C. (English)

1 reference

5 December 2017

J P Cervoni

1

1 reference

5 December 2017

F Degos

series ordinal

2

1 reference

5 December 2017

P Marcellin

series ordinal

3

1 reference

5 December 2017

S Erlinger

series ordinal

4

1 reference

5 December 2017

publication date

1 December 1997

1 reference

5 December 2017

published in

Journal of Hepatology

1 reference

5 December 2017

volume

27

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

1113-1116

1 reference

Liver failure due to recombinant alpha interferon for chronic myelogenous leukaemia

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Liver failure due to recombinant alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Hepatic injury after interferon-alpha therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Lethality of interferon preparations for newborn mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Interferon-induced enzymatic activities and their role in the antiviral state

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Changes in ultrastructure of hepatocytes and liver test results before, during, and after treatment with interferon-beta in patients with HB(e)Ag-positive chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Biological basis for the clinical use of interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Hazards of interferon treatment in patients with autoimmune chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Autoimmune chronic hepatitis exacerbated by alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980157-2

7 January 2021

10.1016/S0168-8278(97)80157-2

Identifiers

DOI

1 reference

5 December 2017

1 reference